Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses

Overview of attention for article published in Clinical Lymphoma, Myeloma & Leukemia, November 2025

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 1 news outlet

twitter: 14 X users

Readers on

mendeley: 18 Mendeley

So far, Altmetric has seen 15 X posts from 14 X users, with an upper bound of 36,436 followers.

The cancer center’s Attaya Suvannasankha, MD, and colleagues contributed to a newly published article in Clinical Lymphoma, Myeloma & Leukemia. Learn more: https://t.co/ZWW8lUtsc9. #ResearchCuresCancer #NCIcomprehensive https://t.co/zZb58A09dT

RT @Myeloma_Doc: #Myeloma Paper of the Day: LINKER-MM1 long-term f/u show ORR 71% (≥CR 52%), median DOR & OS 29.4 & 31.4 mos, PFS NR, MRD-…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 11 additional X posts.